Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to characterize the correlation between Peg-IFN-α antiviral effect and IFN-inducing signaling in CHB patients who switched to Peg-IFN from long time entecavir (ETV) treatment, we investigated the dynamic expression of interferon-stimulated genes (ISGs), including STAT1, MX, and a negative regulatory factor, suppressor of cytokine signaling 3(SOCS3), which negatively regulate IFN JAK-STAT signaling pathway by interacting with STAT1 and STAT2, in peripheral blood and paired liver samples, obtained from 54 CHB patients enrolled in a clinical trial, OSST study.
|
28988797 |
2017 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination with ETV and PEG-IFN could be an option for treatment of CHB patients especially in those with baseline HBsAg levels of less than 3.5 log U/ml.
|
29438098 |
2018 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the effect of Peg-IFN therapy in treatment-experienced CHB patients.
|
25835020 |
2015 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression levels of STAT-1 and APOBEC3G in the liver of CHB patients with a complete response to IFN-α are significantly higher than that of the patients with non-response to IFN-α treatment.
|
20957108 |
2010 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic hepatitis B (CHB) patients with advanced fibrosis are often not considered for treatment with peginterferon (PEG-IFN) because IFN therapy may precipitate immunological flares, potentially inducing hepatic decompensation.
|
17604363 |
2007 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients.
|
26436722 |
2016 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicated that serum TCHO was associated with PEG-IFN-α therapeutic response in HBeAg-positive CHB patients which suggested that serum TCHO could be useful as an auxiliary clinical factor to predict poor efficacy of PEG-IFN-α therapy.
|
30520414 |
2019 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
On-treatment HBsAg decline during PEG-IFN therapy for HBeAg-positive CHB depends upon HBV genotype.
|
22267464 |
2012 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate possible involvement of estrogen receptor α (ESR1) in responding to pegylated interferon alpha-2a (PEG IFNα-2a) therapy in chronic hepatitis B (CHB) patients.
|
26485345 |
2016 |
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that SNP rs4646536 in the CYP27B1 gene is a predictive factor of response to PEG-IFN therapy in Thai patients with CHB.
|
28291736 |
2017 |
Complete atrioventricular block
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using independent and agnostic bioinformatics approaches, CD45<sup>+</sup>CD11c<sup>+</sup> and CD45<sup>+</sup>CD11c<sup>-</sup> human leukocytes flow sorted from the CHB hearts highly expressed type I IFN response genes inclusive of SIGLEC1.
|
30518570 |
2019 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the relationship between interleukin-21 (IL-21) and interleukin-21 receptor (IL-21R) polymorphisms and the response to peginterferon alfa (PEG-IFN α) therapy in HBeAg-positive chronic hepatitis B (CHB) patients.A total of 143 HBeAg-positive CHB patients treated for 48 weeks with PEG-IFN α and followed up for 24 weeks post-treatment were retrospectively evaluated.
|
29879024 |
2018 |
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aimed to investigate the expression and function of TLR8 in peripheral blood mononuclear cells (PBMCs) of chronic hepatitis B (CHB) patients and its alteration during peg-IFN-α-2a therapy.
|
28236535 |
2017 |
Complete atrioventricular block
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The MOV10, A3G, and IFN-α mRNA levels in CHB group was significantly lower than those in the control group (P<0.01, P<0.05, P<0.01, respectively).
|
24871977 |
2014 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
(Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients.
|
30715261 |
2019 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peg-IFN-α monotherapy is a treatment option recommended by local and international clinical practice guidelines to help more CHB patients achieve a sustained off-treatment virological response, which is particularly appropriate for relatively young patients who demand a finite treatment approach.
|
31380584 |
2019 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Understanding these factors can help determine personalized PEG-IFN therapy for CHB patients.
|
24373087 |
2014 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data from this study demonstrated for the first time that IP-10 polymorphism is independently associated with treatment response to PEG-IFN in patients with HBeAg-positive CHB.
|
26376789 |
2016 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the limited efficacy is the main factor restricting the use of PEG-IFNα in CHB and therefore identifying the predictors of response is of great clinical importance.
|
24373089 |
2014 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
Presence of anti-IFN antibodies was assessed at baseline and at 3 and 6 months post-treatment in 323 CHB patients treated with PEG-IFN for 1 year.
|
24296674 |
2014 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated whether Thymopentin (TP5) and interferon (IFN-a) had a synergic effect on HBV cccDNA and the effect of TP5 addition therapy on HBsAg clearance in CHB patients.
|
30860474 |
2019 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN-λ has recently been tested in clinical trials of chronic hepatitis B virus infection (CHB), with the advantage that side effects may be limited compared with IFN-α, as IFN-λ receptors are found only in epithelial cells.
|
30097535 |
2018 |
Complete atrioventricular block
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Through PCR array, we found higher baseline level of IFN-induced transmembrane protein 2 (IFITM2) mRNA and lower baseline level of IFNα mRNA in peripheral blood mononuclear cells (PBMCs) of CHB patients with suboptimal response to IFNα treatment.
|
30723923 |
2019 |
Complete atrioventricular block
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Peg-IFN combined with TDF may increase the virological response rate, biochemical response rate, and HBsAg loss rate in patients with CHB infection.
|
31114265 |
2019 |
Complete atrioventricular block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared to the rs7574865 GT/TT genotype, the GG genotype (a risk factor of CHB and hepatitis B virus-related hepatocellular carcinoma) was significantly associated with a reduced SVR rate in both patients who received IFNα-2b therapy (21.1% versus 37.2%, P = 0.01) and those who received pegylated IFNα-2a therapy (18.0% versus 41.2%, P = 9.74 × 10(-5) ).
|
26704347 |
2016 |